<DOC>
	<DOCNO>NCT00034775</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability long-acting injectable formulation risperidone switch oral antipsychotic patient schizophrenia .</brief_summary>
	<brief_title>A Study Assess Safety Tolerabiltiy Associated With Switch From Oral Antipsychotic Medications Long-acting Injectable Risperidone Patients With Schizophrenia .</brief_title>
	<detailed_description>For schizophrenia patient take oral antipsychotic medication , long-acting injectable formulation antipsychotic medication may eliminate need daily medication enhance patient compliance treatment regimen . This open-label , non-randomized study formulation risperidone ( coated microspheres ) inject muscle 2 week interval 12 week patient schizophrenia . The study two phase : first 4 week , patient continue treatment present medication ( haloperidol , quetiapine fumarate , olanzapine ) ; second phase 12 week , patient receive injectable formulation risperidone , continue receive present medication 3 week risperidone long-acting injectable reach effective drug level . For remainder 12-week treatment phase , patient receive injectable risperidone every 2 week . Safety evaluation include incidence , type , severity treatment-emergent adverse event throughout study ; vital sign ( pulse , blood pressure ) , clinical laboratory test ( hematology , biochemistry , urinalysis ) , electrocardiogram ( ECGs ) , extrapyramidial symptom also monitor specified interval . Assessments effectiveness include Positive Negative Syndrome Scale ( PANSS ) overall severity illness measure Clinical Global Impression ( CGI ) scale . The study hypothesis long-acting injectible risperidone well-tolerated treatment patient schizophrenia switch treatment oral antipsychotic . Risperidone injection ( 25 milligram [ mg ] ) every 2 week 12 week . Investigator may adjust dosage 37.5mg 50 mg ( maximum ) supplement risperidone injection risperidone tablet ( 1mg ) , accord symptom treatment response .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) currently treat either oral haloperidol , quetiapine fumarate , olanzapine 4 month prior trial entry Positive Negative Syndrome Scale ( PANSS ) total score &lt; =80 score &lt; = 4 follow PANSS item : conceptual disorganization , hallucinatory behavior , suspiciousness , unusual thought content body mass index &lt; = 35 start study . Meet DSMIV criterion Axis I diagnosis schizophrenia diagnosis substance dependence ( except nicotine caffeine dependence ) history neuroleptic malignant syndrome , rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness history disease central nervous system , stroke , Parkinson 's disease , Alzheimer 's disease , Huntington 's disease know hypersensitivity , intolerance , unresponsiveness risperidone pregnant nursing female , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>intramuscular injection</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>risperidone</keyword>
</DOC>